| Literature DB >> 35759933 |
Sara El-Hanboushy1, Hoda M Marzouk2, Yasmin M Fayez3, Mohamed Abdelkawy1, Hayam M Lotfy1.
Abstract
Recent studies have reported that using certain antihypertensive therapies such as angiotensin II receptor blockers (ARBs) and calcium channel blocker (CCBs) is associated with reduction of fatal outcomes and improving clinical characteristics of patients suffering from hypertension during coronavirus pandemic. Thus, in the current work an effective, innovative and eco-friendly spectrophotometric manner namely, parent spectrum extraction (PSE)was established for evaluation of recommended triple antihypertensive combination therapies incorporate valsartan (VAL) as ARBs, amlodipine besylate as CCBs (AML) and hydrochlorothiazide (HCT)as diuretic into single-pill in challengeable ratio. PSE manner composed of two complementary steps, auxiliary resolution coupled with data analysis resolution(DAR)and it is characterized by resolving the spectral bands of the drugs and extraction of their discrete parent spectra (D0); accordingly, enabling determination of each analyte at its λmax. Auxiliary resolution of AML in triple mixture was applied to decrease complexity of overlapped spectra via constant multiplication (CM) followed by spectrum subtraction (SS) to obtain resolved mixture of VAL and HCT while data analysis resolution (DAR) of this binary mixture was applied via one of three novel methods namely, absorbance extraction (AE), peak-amplitude extraction (PE) and ratio extraction (RE) along with SS method. The proposed methods had analyzed VAL, AML and HCT in the range of 4.0-44.0 µg/mL, 4.0-40.0 µg/mL and 2.0-24.0 µg/mL, respectively with an excellent correlation coefficient (r ≥ 0.9999). Further, the proposed methods in PSR manner were validated as stated by ICH guidelines and it was found that accuracy and precision results are within the acceptable limit. The suggested procedures were effectively utilized for the concurrent quantification of VAL, AML and HCT in synthetic mixtures and tablets. The greenness of the proposed spectrophotometric methods was evaluated by National Environmental Methods Index (NEMI), the Analytical Eco-Scale, the Green Analytical Procedure Index (GAPI) and Analytical greenness metric (AGREE) where the four tools affirmed the eco-friendly nature of the proposed methods. A comparison between the outcomes of the studied methods with the official and reported ones was performed and no statistical difference was arisen between the methods regarding to accuracy and precision.The achieved results along with the simplicity, affordability and low-cost of the proposed methods recommended their appropriateness for the regular quality control examination and analysis of pure materials and pharmaceutical formulations as well as their applicability for the spectralprint recognition of the studied drugs.Entities:
Keywords: Absorbance extraction; Eco-friendly; Parent spectrum extraction; Peak-amplitude extraction; Ratio extraction; Spectralprint recognition
Mesh:
Substances:
Year: 2022 PMID: 35759933 PMCID: PMC9212944 DOI: 10.1016/j.saa.2022.121523
Source DB: PubMed Journal: Spectrochim Acta A Mol Biomol Spectrosc ISSN: 1386-1425 Impact factor: 4.831
Fig. 1The chemical structures of the proposed drugs: (a) Valsartan, (b) Amlodipine besylate and (C) Hydrochlorothiazide.
Diagram 1Representing the effect of antihypertensive medicines on clinical characteristics and fatal findings in COVID-19 patients.
Fig. 2Parent zero order absorption spectra of VAL (----) 16.0 µg/mL, AML (.....) 6.0 µg/mL and HCT (—) 2.5 µg/mL.
Fig. 3Resolved zero order absorption spectra of the binary mixture of VAL (----) 16.0 µg/mL and HCT (—) 2.5 µg/mL showing absorbance factor using λ1 (270.5 nm) and λ2 (330 nm).
Fig. 4Resolved ratio spectrum of the binary mixture of VAL (----) 16.0 µg/mL and HCT (—) 2.5 µg/mL using AML 28.0 µg/mL as a divisor showing amplitude factor using λ1(274.5 nm) and λ2 (330 nm).
Fig. 5Resolved ratio spectrum of the binary mixture of VAL (----) 16.0 µg/mL and HCT (—) 2.5 µg/mL using VAL 28.0 µg/mL as a divisor showing the selected λ1 (275 nm) and λ2 (250 nm).
Regression parameters and validation sheet for determination of pure VAL, AML and HCT by the proposed methods.
| Drug | VAL | AML | HCT |
|---|---|---|---|
| 4.0–44.0 | 4.0–40.0 | 2.0–24.0 | |
| Slope | 0.0318 | 0.0366 | 0.068 |
| Intercept | 0.0112 | 0.002 | 0.0062 |
| Correlation Coefficient (r) | 1.0000 | 1.0000 | 0.9999 |
| 100.19 ± 0.59 | 99.67 ± 0.59 | 100.03 ± 0.89 | |
| 0.482 | 0.585 | 0.660 | |
| 0.654 | 0.850 | 0.896 | |
Accuracy was checked using concentrations (6.0 µg/mL, 24.0 µg/mL and 40.0 µg/mL), (6.0 µg/mL, 25.0 µg/mL and 38.0 µg/mL) and (4.0 µg/mL, 16.0 µg/mL and 23.0 µg/mL) for, VAL, AML and HCT respectively.
and are repeatability and intermediate precision respectively (n = 9) relative standard deviation of three different concentrations in triplicate (8.0 µg/mL, 28.0 µg/mL and 36.0 µg/mL) for both VAL and AML, while (6.0 µg/mL, 14.0 µg/mL and 22.0 µg/mL) for HCT.
Determination of the studied drugs in the synthetic mixtures by the proposed spectrophotometric methods.
| Ternary Mixture | |||||||
|---|---|---|---|---|---|---|---|
| Recovery%*± SD | |||||||
| VAL:AML: HCT | VAL(D0) | AML(D0) | HCT(D0) | ||||
| Ratio (µg/mL) | SS of D0 HCT via AE | SS of D0 HCT | SS of D0 HCT | CM | AE | PE | RE |
| (32.0:6.0:2.5) ** | 98.86 | 100.23 | 99.80 | 100.24 | 100.51 | 100.36 | 99.26 |
| (16.0:6.0:2.5) ** | 100.36 | 99.45 | 99.28 | 99.38 | 99.46 | 99.52 | 99.84 |
| (10.0:10.0:10.0) | 99.57 | 100.68 | 100.25 | 100.35 | 100.82 | 99.87 | 100.41 |
| (42.0:7.0:14.0) | — | — | 100.44 | 99.44 | — | — | 100.25 |
| (20.0:10.0:20.0) | 100.44 | 100.55 | 98.56 | 99.58 | 100.23 | 100.24 | 99.56 |
* Average of 3 replicates.
** Ratio as dosage forms enriched with 5.0 µg/mL AML.
Quantitative estimation of valsartan, amlodipine and hydrochlorothiazide in the two formulas of Exforge HCT® Tablets.
| Pharmaceutical dosage form | VAL (D0) | AML (D0) | HCT (D0) | ||||
|---|---|---|---|---|---|---|---|
| SS of D0 HCT | SS of D0HCT | SS of D0HCT | CM | AE | PE | RE | |
| Pharmaceutical dosage form | 100.16 ± 0.57 | 100.66 ± 0.45 | 99.89 ± 0.53 | 99.10 ± 0.64 | 99.20 ± 0.54 | 99.58 ± 0.70 | |
| Pharmaceutical dosage form | 100.41 ± 0.50 | 100.33 ± 0.37 | 100.08 ± 0.64 | 100.12 ± 0.67 | 100.80 ± 0.55 | 100.93 ± 0.67 | 100.82 ± 0.52 |
Average of six experiments.
Enriched with 5.0 µg/mL of AML before being analyzed by the proposed methods.
Statistical comparison of the results obtained by the proposed spectrophotometric methods and those obtained by the reported one for the determination of the cited drugs in the two studied pharmaceutical formulations.
| Parameter | Exforge HCT® Formula I (VAL: AML: HCT) (32.0: 1.0:2.5) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| VAL (D0) | AML(D0) | HCT(D0) | ||||||||
| Reported method | SS of D0 HCT | SS of D0 HCT | SS of D0 HCT | Reported method | CM | Reported method | AE | PE | RE | |
| Mean | 100.50 | 100.16 | 100.66 | 99.89 | 98.66 | 99.10 | 99.19 | 99.20 | 99.58 | 99.80 |
| S.D | 0.60 | 0.57 | 0.45 | 0.53 | 0.48 | 0.64 | 0.56 | 0.54 | 0.70 | 0.42 |
| n | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Variance | 0.3600 | 0.3249 | 0.2025 | 0.2809 | 0.2304 | 0.4096 | 0.3136 | 0.2916 | 0.4900 | 0.1764 |
| Student's | – | 1.006 | 0.522 | 1.866 | – | 1.347 | – | 0.031 | 1.066 | 2.134 |
| F test | – | 1.11 | 1.78 | 1.28 | – | 1.78 | – | 1.08 | 1.56 | 1.78 |
| Exforge HCT® Formula II (VAL: AML:HCT) (16.0:1.0:2.5) | ||||||||||
| VAL | AML | HCT | ||||||||
| Parameters | Reported method | SS of D0 HCT via AE | SS of D0 HCT via PE | SS of D0 HCT via RE | Reported method | CM | Reported method | AE | PE | RE |
| Mean | 100.71 | 100.41 | 100.33 | 100.08 | 100.05 | 100.12 | 101.40 | 100.80 | 100.93 | 100.82 |
| SD | 0.43 | 0.50 | 0.37 | 0.64 | 0.68 | 0.67 | 0.81 | 0.55 | 0.67 | 0.52 |
| n | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Variance | 0.1849 | 0.2500 | 0.1369 | 0.4096 | 0.4624 | 0.4489 | 0.6561 | 0.3025 | 0.4489 | 0.2704 |
| Student's | – | 1.114 | 1.641 | 2.002 | – | 0.180 | – | 1.501 | 1.095 | 1.476 |
| F test | – | 1.72 | 1.35 | 2.22 | – | 0.97 | – | 2.17 | 1.46 | 2.43 |
Reported UHPLC method using C18 column and mobile phase consisting of acetonitrile-methanol-phosphate buffer, 25:50:25, by volume, pH 2.8.
The figures in parenthesis are the corresponding theoretical values at P = 0.05.
Statistical analysis for the results obtained by the proposed methods and the official HPLC methods for analysis of the cited drugs in their pure forms.
| Drug | VAL | AML | HCT | |||
|---|---|---|---|---|---|---|
| parameters | D0 | Official method | D0 | Official method | D0 | Official method |
| Mean | 100.08 | 99.51 | 100.21 | 99.74 | 99.95 | 99.79 |
| SD | 0.62 | 0.55 | 0.39 | 0.52 | 0.68 | 0.65 |
| n | 6 | 6 | 6 | 6 | 7 | 6 |
| Variance | 0.3844 | 0.3025 | 0.1521 | 0.2704 | 0.8424 | 0.4225 |
| Student's | 2.228 | – | 2.228 | — | 2.201 | – |
| Student's | 1.685 | – | 1.772 | — | 0.433 | – |
| F (tab.) | 5.05 | – | 5.05 | — | 4.95 | – |
| F (cal.) | 1.27 | – | 1.78 | — | 1.99 | – |
Official USP methods for determination of VAL, AML and HCT (RP-HPLC).
The figures in parenthesis are the corresponding theoretical values at P = 0.05.
Results of ANOVA (single factor) for comparison of the results obtained by the proposed methods and the official methods for determination of the proposed drugs in their pure powder forms.
| Source of variation | Sum of squares | DF | Mean Square | F value | P value | F crit |
|---|---|---|---|---|---|---|
| Between exp. | 0.9747 | 1 | 0.9747 | 2.857883 | 0.121807 | 4.964603 |
| Within exp. | 3.410566667 | 10 | 0. 341,057 | |||
| Total | 4.385266667 | 11 | ||||
| Between exp. | 0.6627 | 1 | 0.6627 | 3.170207 | 0.10534 | 4.964603 |
| Within exp. | 2.0904 | 10 | 0.20904 | |||
| Total | 2.7531 | 11 | ||||
| Between exp. | 0.087958 | 1 | 0.087958 | 0.19628 | 0.666327 | 4.844336 |
| Within exp. | 4.92935 | 11 | 0.448123 | |||
| Total | 5.017308 | 12 | ||||
-At the 0.05 level.
-The population means are not significantly different.
Spectralprint recognition index for Valsartan (VAL), Amlodipine (AML) and Hydrochlorothiazide (HCT) in Exforge HCT® tablets.
| Tablet No. | Exforge HCT® Tablets | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Formula I | Formula II | |||||||||||||
| VAL | AML | HCT | VAL | AML | HCT | |||||||||
| Spectralprint Index | Spectralprint Index | |||||||||||||
| SS of D0HCT | SS of D0HCT | SS of D0HCT | CM | AE | PE | RE | SS of D0HCT | SS of D0HCT | SS of D0HCT | CM | AE | PE | RE | |
| Tablet 1 | 0.991 | 0.991 | 0.999 | 0.988 | 0.989 | 0.993 | 0.996 | 0.996 | 0.99 | 0.994 | 0.999 | 0.999 | 0.992 | 0.993 |
| Tablet 2 | 0.996 | 0.998 | 0.994 | 0.989 | 0.995 | 0.99 | 0.999 | 0.998 | 0.999 | 0.996 | 0.994 | 0.994 | 0.991 | 0.997 |
| Tablet 3 | 0.998 | 0.996 | 0.992 | 0.999 | 0.99 | 0.987 | 0.998 | 0.994 | 0.998 | 0.999 | 0.995 | 0.995 | 0.99 | 0.994 |
| Tablet 4 | 0.997 | 0.997 | 0.995 | 0.987 | 0.992 | 0.994 | 0.895 | 0.993 | 0.997 | 0.998 | 0.993 | 0.993 | 0.989 | 0.995 |
| Tablet 5 | 0.992 | 0.993 | 0.995 | 0.996 | 0.99 | 0.991 | 0.988 | 0.994 | 0.993 | 0.997 | 0.998 | 0.998 | 0.991 | 0.996 |
| Tablet 6 | 0.985 | 0.998 | 0.999 | 0.996 | 0.991 | 0.987 | 0.992 | 0.992 | 0.994 | 0.993 | 0.996 | 0.996 | 0.986 | 0.995 |
| Tablet 7 | 0.988 | 0.991 | 0.998 | 0.998 | 0.988 | 0.999 | 0.999 | 0.994 | 0.992 | 0.995 | 0.998 | 0.998 | 0.988 | 0.994 |
| Tablet 8 | 0.999 | 0.993 | 0.994 | 0.994 | 0.989 | 0.986 | 0.995 | 0.998 | 0.995 | 0.996 | 0.997 | 0.997 | 0.991 | 0.993 |
| Tablet 9 | 0.996 | 0.989 | 0.995 | 0.997 | 0.99 | 0.998 | 0.994 | 0.997 | 0.996 | 0.992 | 0.992 | 0.992 | 0.988 | 0.995 |
| Tablet 10 | 0.998 | 0.995 | 0.994 | 0.998 | 0.992 | 0.994 | 0.988 | 0.999 | 0.992 | 0.996 | 0.994 | 0.994 | 0.991 | 0.995 |
| Mean | ||||||||||||||
| SD | ||||||||||||||
Greenness assessment of the two proposed spectrophotometric methods according to Eco-Scale, NEMI, GAPI and AGREE tools.
| Eco-Scale assessment | NEMI tool | GAPI tool | AGREE tool | |
| Parameters | Penalty points | |||
| Ethanol* | 4 | |||
| Energy consumption | 0 | |||
| Occupational hazards | 0 | |||
| Waste | 3 | |||
| 7 | ||||
| 93 | ||||
*Ethanol is given a signal word ‘danger’ with two pictograms and consumed volume per sample analysis is <10 mL (sample cuvette).